Serum, urine, tissue, and body fluids were collected from 40 adult patients who were receiving imipenem/cilastatin treatment for serious infections. Thirty-two patients were given 1 g every 6 h (4 g/day), and eight received 500 mg (2 g/day). Mean peak concentrations in serum were 34.9 ± 4.0 p.g/ml for the 1-g dose and 26.6 ± 2.5 ,ug/ml for the 500-mg dose. Trough levels were 3.1 and 1.0 ,ug/ml, respectively. Imipenem (formerly N-formimidoyl thienamycin [MK0787]) is a stabilized amidine derivative of thienamycin, the first member of a new class of beta-lactam antibiotics, the carbapenems, which are characterized by their possession of a desthiocarbapenem nucleus (6, 8) . The combination of impressive activity against most aerobic and anaerobic bacterial species (9, 15) and the relatively low incidence of toxic reactions that is typical for the beta-lactam antibiotics as a group (5) Most patients received a dosage of 1 g of imipenem combined with 1 g of cilastatin intravenously every 6 h, although late in the trial some were given 500 mg of each to conserve the drug. Unless otherwise noted, data presented below are from those patients who received the higher dose. A 1-g amount of imipenem/cilastatin was dissolved in either 200 ml of isotonic saline or 5% dextrose in water and infused over 30 to 60 min. Because of the large volume, most infusions required 60 min.
Imipenem (formerly N-formimidoyl thienamycin [MK0787] ) is a stabilized amidine derivative of thienamycin, the first member of a new class of beta-lactam antibiotics, the carbapenems, which are characterized by their possession of a desthiocarbapenem nucleus (6, 8) . The combination of impressive activity against most aerobic and anaerobic bacterial species (9, 15) and the relatively low incidence of toxic reactions that is typical for the beta-lactam antibiotics as a group (5) makes imipenem an attractive choice for the treatment of complicated infections in seriously ill patients. Because imipenem is hydrolyzed by the renal proximal brush border enzyme dehydropeptidase I (8) , it is coadministered in clinical usage with cilastatin sodium, a specific and highly active dipeptidase inhibitor that improves plasma concentration and the area under the plasma concentration curve and markedly increases urinary excretion of the unmetabolized drug (11) . Studies of normal human volunteers have described the pharmacokinetics of multipledose imipenem/cilastatin (4) and the degree of drug recovery from urine and feces (13) . A recent clinical study of highdosage (1 g every 6 h) imipenem/cilastatin therapy for infections permitted similar measurements in seriously ill patients (16) . This paper reports imipenem plasma pharmacokinetics and urinary excretion in these patients, as well as drug concentrations in various other body fluids and inflammatory exudates. (12) showed that the half-life at alpha phase (t112,) equaled 10 (10) , gastric contents (7), duodenal T-tube fluid (1), and ileostomy fluid (2) were assayed. All specimens were iced at the bedside and promptly processed, as described above for blood and urine. Clinical conditions made it impossible to control the interval between intravenous drug administration and collection of the various specimens. Bone from sites of osteomyelitis was obtained during debridement, rinsed for 30 s in normal saline to remove blood and debris, and lyophilized. Dried specimens were ground with a mortar and pestle containing morpholinoethane sulfonate-ethylene glycol stabilizing buffer and extracted for 8 h at 4°C with occasional agitation. Then the specimens were centrifuged and the supernatants stored at -70°C until assayed. The sclerotic nature of the diseased bone made the grinding of some specimens incomplete. Because of the unpredictable nature of surgical scheduling, specimens were obtained anywhere from 20 min to 5 h after drug infusion.
MATERIALS AND METHODS
Imipenem was quantitated by using a disk agar diffusion assay of Bacillus subtilis ATCC 12432, which was seeded onto Mueller-Hinton agar (Difco). Over the study period, 1 .00 ,ug of imipenem per ml assayed at 1.01 ± 0.04 ,ug/ml, corresponding to a critical variance of 3.4%. To verify that zones of inhibition actually represented antibiotic activity, specimens from bile, gastric contents, and drains were treated with hydroxylamine to inactivate imipenem (2) . No zones were found on retesting after such treatment.
Pharmacokinetic calculations. The log imipenem concentration in plasma time data was plotted for each patient. The elimination rate constant (k) was determined from three postinfusion serum concentrations by using a linear regression computer program (7). The half-life (tj12) was obtained by dividing k into 0.693. The apparent volume of distribution (V) was computed from the post-distribution time data based on a method for multiple intravenous infusions (14) :
where ko is the imipenem infusion rate in milligrams per hour, k is the elimination rate constant in hours-', T is the infusion period in hours (doses infused over 1 h), Cmax is the peak plasma concentration after a 1-h infusion, and Cmin is the concentration in milligrams per milliliter immediately before the dose was infused.
Total body clearance (CLt) was computed by multiplying k and V, and creatinine clearance was calculated by using 6-h urine collections and serum creatinine determinations collected during the urine collection period. To examine the relationship between age and imipenem clearance, and between elimination rate and creatinine clearance, bivariate linear regression analysis and correlation analysis were performed. The variables were analyzed by a least-square linear regression method. The squared correlation coefficient (r2) obtained from the computer analysis of the regression was used as an indicator of the relationship between the variables. RESULTS Plasma concentrations and kinetics. Peak and trough plasma concentrations of imipenem after 1-g intravenous (i.v.) doses were measured in 31 patients, and following 500-mg doses in 8 patients (Fig. 1) . Mean peaks were 34.9 ± standard deviation of 4.0 ,ug/ml (range, 16.7 to 67.3 j.Lg/ml) for 1 g and 26.6 ± 2.5 jig/ml (range, 19.3 to 38.3) for 500 mg.
Trough levels were 3.1 ,ug/ml and 1.0 g±g for the two groups, respectively. Six patients were studied within the first 3 days after initiating treatment (early) and again while still receiving the drug 10 to 42 days later (late). No evidence of either drug accumulation or more rapid clearance was found, as mean peaks were 41.4 ± 5.2 ,ug/ml and 36.6 ± 3.9 ,ug/ml, respectively. Seven patients had a comparison of peak plasma levels performed after 30-versus 60-min infusion of 1-g doses: mean concentrations were 32.9 ± 2.7 ,ug/ml after 30-min infusions and 28.5 ± 2.7 ,ug/ml after 60-min infusions.
The plasma t112 of impenem was calculated from peak, midpoint, and trough plasma concentrations in 26 patients by using the Zaske-Sawchuck method (14) . Table 1 Moreover, total body clearance fell as the age of the patients rose: r = <0.47, P < 0.001 (CLt = -0.0019 age + 0.276).
Urinary recovery. Twenty-five patients had urine collected throughout a 6-h dosing interval. Mean urinary antibiotic recovery was 39.1 ± 12.8%, with a range from 15.0 to 59.2% (Fig. 2) . Six patients with renal transplants had recoveries similar to that of the group as a whole. Recovery did not correlate with CLCR until the latter was below 15 ml/min; but, in two such patients, urinary recovery was markedly reduced.
Concentrations in gastrointestinal secretions. Imipenem enters gastrointestinal tract secretions. Table 2 intraperitoneal, intrathoracic, and pelvic infections (Table  3) . Clinically significant imipenem concentrations were detected in all specimens. Similarly, the drug was found in seven of seven sputum specimens tested. Bone specimens were obtained from the debridement of osteomyelitis in 10 cases while the patients were receiving i.v. imipenem (Table  2) . Generally, the highest concentrations (expressed in micrograms per gram of dried bone) were found in bone taken within 1 h after infusion, and the lowest after a longer delay. Nonetheless, the drug was detectable in all specimens.
DISCUSSION
This paper differs from previous reports of imipenem pharmacokinetics (4, 11, 13) in several ways: (i) Study subjects were hospitalized patients with serious infections, rather than healthy normal volunteers. Their mean age was 48 years, and many had underlying diseases in addition to their serious infections. (ii) The drug administration was carried out by staff nurses on the regular medical and surigcal in-patient units, rather than in the carefully moni- (10) suggested that diarrhea would not be a side effect of this drug (1) . However, occasional diarrhea has occurred in some clinical trials, including several cases associated with the isolation of Clostridium difficile toxin (3, 5) . The gastrointestinal fluid imipenem concentrations reported here (0.4 to 2.5 ,ug/ml), although much lower than plasma drug levels, are above the MIC for 90% of the strains for most of the common aerobic and anaerobic stool bacteria (6, 9, 15) . Thus, changes in stool flora may occur at higher doses of imipenem.
The concentrations of imipenem reported herein for inflammatory exudates must be considered minimum estimates because the specimens had been in situ in an acid environment, at 380 to 400, for an undetermined time prior to collection and icing. Both acid pH and body temperature are known to hasten breakdown of the drug (12) . Nonetheless, the mean concentrations of 7.2 ,ug/ml in wound drainage and 4.4 ,ug/mnl in sputum are above the MIC for 90% of the strains for most bacteria. The extraction of antibiotic from most bone specimens was complicated by the sclerotic nature of the osteomyelitic tissue reaction. Nonetheless, the drug could be detected in all 10 specimens examined, as long as 5 h after infusion.
